COJ0 Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.23 |
| 52 Week High | kr0.61 |
| 52 Week Low | kr0.15 |
| Beta | 1.29 |
| 1 Month Change | -16.91% |
| 3 Month Change | -19.93% |
| 1 Year Change | -57.06% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| COJ0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -1.6% | -0.5% |
| 1Y | -57.1% | -24.7% | 5.2% |
Return vs Industry: COJ0 underperformed the German Biotechs industry which returned -25.9% over the past year.
Return vs Market: COJ0 underperformed the German Market which returned 6.4% over the past year.
Price Volatility
| COJ0 volatility | |
|---|---|
| COJ0 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: COJ0's share price has been volatile over the past 3 months.
Volatility Over Time: COJ0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 8 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies.
CombiGene AB (publ) Fundamentals Summary
| COJ0 fundamental statistics | |
|---|---|
| Market cap | €5.39m |
| Earnings (TTM) | -€3.05m |
| Revenue (TTM) | €536.62k |
10.0x
P/S Ratio-1.8x
P/E RatioIs COJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COJ0 income statement (TTM) | |
|---|---|
| Revenue | kr6.21m |
| Cost of Revenue | kr26.23m |
| Gross Profit | -kr20.02m |
| Other Expenses | kr15.22m |
| Earnings | -kr35.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | -1.78 |
| Gross Margin | -322.56% |
| Net Profit Margin | -567.69% |
| Debt/Equity Ratio | 0% |
How did COJ0 perform over the long term?
See historical performance and comparison